Tirzepatide did receive FDA approval for OSA in December 2024 (the SURMOUNT-OSA trial), but Medicares coverage update for OSA is still being finalized as of mid-2026
Free radicals contribute to heart failure through direct damage to cardiomyocytes, mitochondrial dysfunction, and the promotion of fibrosis
How were adapting Give people the full picture: oral GLP-1s are exciting, but they are not effortless
GLP-1 supply issues predicted to carry on As GLP-1 supply issues wage on, European regulators have flagged this situation as a serious public health concern, warning that the shortage is unlikely to resolve within the year
Where do things stand now
Our team will walk you through: what to expect, how it works, whether it fits your goals, and what a safe, medically guided protocol looks like